Journal of Molecular Neuroscience

, Volume 33, Issue 3, pp 225–231 | Cite as

Elevated Serum Ghrelin Exerts an Orexigenic Effect that May Maintain Body Mass Index in Patients with Metastatic Neuroendocrine Tumors

  • Hank S. Wang
  • David S. Oh
  • Gordon V. Ohning
  • Joseph R. Pisegna


Ghrelin is a potent orexigenic peptide principally produced in the stomach by a distinct population of neuroendocrine cells in the oxyntic mucosa of the fundus. Exogenous ghrelin given as an intravenous infusion has been shown to increase caloric intake in patients with cancer cachexia. In this study, we hypothesized that elevated endogenous ghrelin, produced by increased neuroendocrine cell tumor burden, also exerts an orexigenic effect helping to maintain body mass index. To evaluate the effect of elevated endogenous ghrelin, 35 patients with neuroendocrine tumors were enrolled, assigning them to one of two groups depending on the presence of hepatic metastases. Following an overnight fast, serum was collected and sent for ghrelin measurement by an outside laboratory. The two groups were well matched for all other relevant clinical variables including subtype of tumor, primary location of tumor and tumor treatment history. Nearly all patients with hepatic metastases had elevated levels of ghrelin compared to the standard reference range given for matched controls. The presence of hepatic metastases was associated with significantly elevated ghrelin levels (p<0.05) and a greater mean body mass index. In addition, we report a positive correlation between serum ghrelin and total tumor surface area and between serum ghrelin and body mass index, suggesting that elevated endogenous ghrelin may be sufficient to overcome any partial ghrelin resistance typically seen in cancer cachexia. These results support the possibility that ghrelin is co-released from neuroendocrine tumors and exerts an orexigenic effect in these patients, helping to maintain their body mass index despite widely disseminated disease.


Ghrelin Metastatic neuroendocrine tumors Endogenous Orexigenic Cancer cachexia Somatostatin Gastrin 



Supported by a Department of Veteran Affairs Merit Review Grant (JRP).


  1. Abou-Saif, A., Gibril, F., Ojeaburu, J. V., Bashir, S., Entsuah, L. K., Asgharian, B., et al. (2003). Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer, 98, 249–261.PubMedCrossRefGoogle Scholar
  2. Akamizu, T., Takaya, K., Irako, T., Hosoda, H., Teramukai, S., Matsuyama, A., et al. (2004). Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. European Journal of Endocrinology, 150, 447–455.PubMedCrossRefGoogle Scholar
  3. Aparicio, T., Ducreux, M., Baudin, E., Sabourin, J. C., De Baere, T., Mitry, E., et al. (2001). Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. European Journal of Cancer, 37, 1014–1019.PubMedCrossRefGoogle Scholar
  4. Bordi, C., D'Adda, T., Azzoni, C., Pilato, F. P., & Caruana, P. (1995). Hypergastrinemia and gastric enterochromaffin-like cells. American Journal of Surgical Pathology, 19, S8–S19.PubMedGoogle Scholar
  5. Broglio, F., Gottero, C., Prodam, F., Gauna, C., Muccioli, G., Papotti, M., et al. (2004). Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. Journal of Clinical Endocrinology and Metabolism, 89, 3062–3065.PubMedCrossRefGoogle Scholar
  6. Corbetta, S., Peracchi, M., Cappiello, V., Lania, A., Lauri, E., Vago, L., et al. (2003). Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: Identification of one pancreatic ghrelinoma. Journal of Clinical Endocrinology and Metabolism, 88, 3117–3120.PubMedCrossRefGoogle Scholar
  7. Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., et al. (2002). Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. New England Journal of Medicine, 346, 1623–1630.PubMedCrossRefGoogle Scholar
  8. Date, Y., Kojima, M., Hosoda, H., Sawaguchi, A., Mondal, M. S., Suganuma, T., et al. (2000). Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology, 141, 4255–4261.PubMedCrossRefGoogle Scholar
  9. Dornonville de la Cour, C., Bjorkqvist, M., Sandvik, A. K., Bakke, I., Zhao, C. M., Chen, D., et al. (2001). A-like cells in the rat stomach contain ghrelin and do not operate under gastrin control. Regulatory Peptides, 99, 141–150.PubMedCrossRefGoogle Scholar
  10. Ducreux, M., Ruszniewski, P., Chayvialle, J. A., Blumberg, J., Cloarec, D., Michel, H., et al. (2000). The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. American Journal of Gastroenterology, 95, 3276–3281.PubMedCrossRefGoogle Scholar
  11. Freda, P. U., Reyes, C. M., Conwell, I. M., Sundeen, R. E., & Wardlaw, S. L. (2003). Serum ghrelin levels in acromegaly: Effects of surgical and long-acting octreotide therapy. Journal of Clinical Endocrinology and Metabolism, 88, 2037–2044.PubMedCrossRefGoogle Scholar
  12. Fykse, V., Sandvik, A. K., Qvigstad, G., Falkmer, S. E., Syversen, U., & Waldum, H. L. (2004). Treatment of ECL cell carcinoids with octreotide LAR. Scandinavian Journal of Gastroenterology, 39, 621–628.PubMedCrossRefGoogle Scholar
  13. Garcia, J. M., Garcia-Touza, M., Hijazi, R. A., Taffet, G., Epner, D., Mann, D., et al. (2005). Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. Journal of Clinical Endocrinology and Metabolism, 90, 2920–2926.PubMedCrossRefGoogle Scholar
  14. Hanada, T., Toshinai, K., Kajimura, N., Nara-Ashizawa, N., Tsukada, T., Hayashi, Y., et al. (2003). Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochemical and Biophysical Research Communications, 301, 275–279.PubMedCrossRefGoogle Scholar
  15. Haqq, A. M., Stadler, D. D., Rosenfeld, R. G., Pratt, K. L., Weigle, D. S., Frayo, R. S., et al. (2003). Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader–Willi syndrome. Journal of Clinical Endocrinology and Metabolism, 88, 3573–3576.PubMedCrossRefGoogle Scholar
  16. Imtiaz, K. E., Monteith, P., & Khaleeli, A. (2000). Complete histological regression of metastatic carcinoid tumour after treatment with octreotide. Clinica Endocrinologica, 53, 755–758.CrossRefGoogle Scholar
  17. Inui, A., Asakawa, A., Bowers, C. Y., Mantovani, G., Laviano, A., Meguid, M. M., et al. (2004). Ghrelin, appetite, and gastric motility: The emerging role of the stomach as an endocrine organ. FASEB Journal, 18, 439–456.PubMedCrossRefGoogle Scholar
  18. Kojima, M. & Kangawa, K. (2005) Ghrelin: Structure and function. Physiological Reviews, 85, 495–522.PubMedCrossRefGoogle Scholar
  19. Neary, N. M., Small, C. J., Wren, A. M., Lee, J. L., Druce, M. R., Palmieri, C., et al. (2004). Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism, 89, 2832–2836.PubMedCrossRefGoogle Scholar
  20. Papotti, M., Cassoni, P., Volante, M., Deghenghi, R., Muccioli, G., & Ghigo, E. (2001). Ghrelin-producing endocrine tumors of the stomach and intestine. Journal of Clinical Endocrinology and Metabolism, 86, 5052–5059.PubMedCrossRefGoogle Scholar
  21. Popovic, V., Miljic, D., Pekic, S., Pesko, P., Djurovic, M., Doknic, M., et al. (2005). Low plasma ghrelin level in gastrectomized patients is accompanied by enhanced sensitivity to the ghrelin-induced growth hormone release. Journal of Clinical Endocrinology and Metabolism, 90, 2187–2191.PubMedCrossRefGoogle Scholar
  22. Ramos, E. J., Suzuki, S., Marks, D., Inui, A., Asakawa, A., & Meguid, M. M. (2004). Cancer anorexia–cachexia syndrome: Cytokines and neuropeptides. Current Opinion in Clinical Nutrition and Metabolic Care, 7, 427–434.PubMedCrossRefGoogle Scholar
  23. Rindi, G., Savio, A., Torsello, A., Zoli, M., Locatelli, V., Cocchi, D., et al. (2002). Ghrelin expression in gut endocrine growths. Histochemistry and Cell Biology, 117, 521–525.PubMedCrossRefGoogle Scholar
  24. Rigamonti, A. E., Pincelli, A. I., Corra, B., Viarengo, R., Bonomo, S. M., Galimberti, D., et al. (2002). Plasma ghrelin concentrations in elderly subjects: Comparison with anorexic and obese patients. Journal of Endocrinology, 175, R1–R5.PubMedCrossRefGoogle Scholar
  25. Shiiya, T., Nakazato, M., Mizuta, M., Date, Y., Mondal, M. S., Tanaka, M., et al. (2002). Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. Journal of Clinical Endocrinology and Metabolism, 87, 240–244.PubMedCrossRefGoogle Scholar
  26. Shimada, M., Date, Y., Mondal, M. S., Toshinai, K., Shimbara, T., Fukunaga, K., et al. (2003). Somatostatin suppresses ghrelin secretion from the rat stomach. Biochemical and Biophysical Research Communications, 302, 520–525.PubMedCrossRefGoogle Scholar
  27. Shimizu, Y., Nagaya, N., Isobe, T., Imazu, M., Okumura, H., Hosoda, H., et al. (2003). Increased plasma ghrelin level in lung cancer cachexia. Clinical Cancer Research, 9, 774–778.PubMedGoogle Scholar
  28. Silva, A. P., Bethmann, K., Raulf, F., & Schmid, H. A. (2005). Regulation of ghrelin secretion by somatostatin analogs in rats. European Journal of Endocrinology, 152, 887–894.PubMedCrossRefGoogle Scholar
  29. Srivastava, A., Kamath, A., Barry, S. A., & Dayal, Y. (2004). Ghrelin expression in hyperplastic and neoplastic proliferations of the enterochromaffin-like (ECL) cells. Endocrine Pathology, 15, 47–54.PubMedCrossRefGoogle Scholar
  30. Thompson, G. B., van Heerden, J. A., Martin Jr., J. K., Schutt, A. J., Ilstrup, D. M., & Carney, J. A. (1985). Carcinoid tumors of the gastrointestinal tract: Presentation, management, and prognosis. Surgery, 98, 1054–1063.PubMedGoogle Scholar
  31. Tschop, M., Weyer, C., Tataranni, P. A., Devanarayan, V., Ravussin, E., & Heiman, M. L. (2001). Circulating ghrelin levels are decreased in human obesity. Diabetes, 50, 707–709.PubMedCrossRefGoogle Scholar
  32. Tsolakis, A. V., Portela-Gomes, G. M., Stridsberg, M., Grimelius, L., Sundin, A., Eriksson, B. K., et al. (2004). Malignant gastric ghrelinoma with hyperghrelinemia. Journal of Clinical Endocrinology and Metabolism, 89, 3739–3744.PubMedCrossRefGoogle Scholar
  33. Volante, M., Allia, E., Gugliotta, P., Funaro, A., Broglio, F., Deghenghi, R., et al. (2002). Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. Journal of Clinical Endocrinology and Metabolism, 87, 1300–1308.PubMedCrossRefGoogle Scholar
  34. Wierup, N., Svensson, H., Mulder, H., & Sundler, F. (2002). The ghrelin cell: A novel developmentally regulated islet cell in the human pancreas. Regulatory Peptides, 107, 63–69.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Hank S. Wang
    • 1
  • David S. Oh
    • 1
    • 2
  • Gordon V. Ohning
    • 1
    • 2
  • Joseph R. Pisegna
    • 1
    • 2
  1. 1.Department of MedicineDavid Geffen School of Medicine at UCLALos AngelesUSA
  2. 2.Division of Gastroenterology and HepatologyVA Greater Los Angeles Healthcare SystemLos AngelesUSA

Personalised recommendations